CYBIN INC
NYSE: CYBN (Cybin Inc.)
Kemas kini terakhir: 8 jam lalu7.18
0.41 (6.06%)
| Penutupan Terdahulu | 6.77 |
| Buka | 6.80 |
| Jumlah Dagangan | 992,826 |
| Purata Dagangan (3B) | 843,560 |
| Modal Pasaran | 358,501,472 |
| Harga / Buku (P/B) | 2.70 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Nov 2025 |
| EPS Cair (TTM) | -4.07 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.08% |
| Nisbah Semasa (MRQ) | 7.75 |
| Aliran Tunai Operasi (OCF TTM) | -101.30 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -57.88 M |
| Pulangan Atas Aset (ROA TTM) | -31.92% |
| Pulangan Atas Ekuiti (ROE TTM) | -42.76% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Cybin Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 0.0 |
| Purata | 0.38 |
|
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 207.96% |
| % Dimiliki oleh Institusi | 42.41% |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |